Literature DB >> 11128235

Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.

A Vermes1, R A Math t, I H van der Sijs, J Dankert, H J Guchelaar.   

Abstract

The objective of this study is to compare and validate three models of flucytosine (5-FC) population pharmacokinetics using three methods of analysis to elucidate which model describes 5-FC pharmacokinetics most accurately and which method is the most suitable for this purpose. Retrospectively, demographic and clinical data of two similar sets of a total of 88 intensive care unit (ICU) patients were gathered for calculation and validation of 5-FC pharmacokinetics respectively. Three pharmacokinetic models were analyzed: a one-compartment with renal elimination (renal model), a one-compartment with renal and metabolic elimination (mixed model), and a two-compartment with renal elimination (two-compartment model). Population pharmacokinetic parameters were calculated using the standard two-stage method (STS), NONMEM, and NPEM. Furthermore, a covariate model was built by NONMEM. Validation of the 10 calculated pharmacokinetic models showed that NONMEM is most suitable for predicting 5-FC population pharmacokinetics. Based upon AIC values, bias and precision, the best results are obtained using a two-compartment model with renal elimination (k(elr) = 0.000858 +/- 0.000143 l/h per mL per min, k12 = 0.0313 +/- 0.0168 h(-1), k21 = 0.0353 +/- 0.0145 h(-1), and Vd = 0.541 +/- 0.084 L/kg; bias = -13.16; 95% CI = -16.77; -9.55; precision = 30.50; 95% CI = 27.47; 33.26) or a two-compartment covariate model as built by NONMEM [Vd (L) = 0.572 x WT, Cl(5FC) (L/h) = 1.69 + 0.0273 x (Cl(cr) (mL/min) - 52.5), k12 = 0.0235 +/- 0.0107 h(-1), and k21 = 0.0375 +/- 0.0147 h(-1); bias = -8.29; 95% CI = -11.63; -4.95; precision = 26.77; 95% CI = 24.24; 29.07]. In conclusion, this study shows that a two-compartment model with renal elimination best describes 5-FC population pharmacokinetics and NONMEM is able to build a two-compartment covariate model that predicts 5-FC levels equally well in our population of ICU patients. Furthermore, NONMEM appeared to be the most suitable method of population pharmacokinetics in our population and for this purpose it offers more reliable and accurate results than NPEM or the STS method.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128235     DOI: 10.1097/00007691-200012000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

Authors:  Annemarie E Brouwer; Hendrikus J M van Kan; Elizabeth Johnson; Adul Rajanuwong; Prapit Teparrukkul; Vannaporn Wuthiekanun; Wirongrong Chierakul; Nick Day; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.

Authors:  William W Hope; Peter A Warn; Andrew Sharp; Susan Howard; Miki Kasai; Arnold Louie; Thomas J Walsh; George L Drusano; David W Denning
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

Review 3.  Treatment of invasive candidiasis in immunocompromised pediatric patients.

Authors:  Brian T Fisher; Theoklis E Zaoutis
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

4.  Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate.

Authors:  Femke de Velde; Brenda C M de Winter; Michael N Neely; Walter M Yamada; Birgit C P Koch; Stephan Harbarth; Elodie von Dach; Teun van Gelder; Angela Huttner; Johan W Mouton
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

5.  Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients.

Authors:  Femke de Velde; Brenda C M de Winter; Michael N Neely; Jan Strojil; Walter M Yamada; Stephan Harbarth; Angela Huttner; Teun van Gelder; Birgit C P Koch; Anouk E Muller
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.